Immune Responses to Two Dose Varivax +/- MMR-II
Measles, Mumps, Rubella
About this trial
This is an interventional prevention trial for Measles focused on measuring Measels, Mumps, Varicella, Rubella, vaccine, children
Eligibility Criteria
Inclusion Criteria: Healthy infants 12 months (+ 4 weeks) of age. Free of obvious health problems as established by medical history and clinical examination before entering into the study. This includes all chronic health problems and immunodeficiencies. Parent/legal guardian has provided signed, written informed consent. Parent/legal guardian expected to be available for entire study. Parent/legal guardian can be reached by telephone. Exclusion Criteria: Former premature infants (<36 weeks). Birth weight < 2500 grams. Significant underlying chronic illness. Immunodeficiency disease or use of immunosuppressive therapy by the participant. Any other condition that in the clinical judgment of the investigator might interfere with vaccine evaluation. Allergy to any components of the vaccine, including anaphylaxis or anaphylaxoid reaction to neomycin or eggs for MMR-II, and/or hypersensitivity to gelatin and anaphylaxis or anaphylaxoid reaction to neomycin for Varivax. Plans for participation in another clinical trial with an investigational drug or vaccine for the duration of this study. Blood products within 3 months prior to initial enrollment. Previous receipt of MMR and Varivax or ProQuad.
Sites / Locations
- Stanford University